纯度 | >85%SDS-PAGE. |
种属 | Human |
靶点 | HMBS |
Uniprot No | P08397 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 2-361aa |
氨基酸序列 | SGNGNAAAT AEENSPKMRV IRVGTRKSQL ARIQTDSVVA TLKASYPGLQ FEIIAMSTTG DKILDTALSK IGEKSLFTKE LEHALEKNEV DLVVHSLKDL PTVLPPGFTI GAICKRENPH DAVVFHPKFV GKTLETLPEK SVVGTSSLRR AAQLQRKFPH LEFRSIRGNL NTRLRKLDEQ QEFSAIILAT AGLQRMGWHN RVGQILHPEE CMYAVGQGAL GVEVRAKDQD ILDLVGVLHD PETLLRCIAE RAFLRHLEGG CSVPVAVHTA MKDGQLYLTG GVWSLDGSDS IQETMQATIH VPAQHEDGPE DDPQLVGITA RNIPRGPQLA AQNLGISLAN LLLSKGAKNI LDVARQLNDA H |
预测分子量 | kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HMBS(羟甲基胆素合酶)重组蛋白的3篇代表性文献,按研究主题分类简要概括:
---
1. **文献名称**:*Expression and characterization of human hydroxymethylbilane synthase in Escherichia coli*
**作者**:J. Wang et al.
**摘要**:报道了人源HMBS基因在大肠杆菌中的重组表达及纯化方法,验证了其酶活性,并探讨了温度对蛋白可溶性的影响。
2. **文献名称**:*Crystal structure of hydroxymethylbilane synthase complexed with substrate analogues*
**作者**:K. Lou et al.
**摘要**:通过X射线晶体学解析了重组HMBS蛋白与底物类似物的复合物结构,揭示了催化机制中关键氨基酸残基的作用。
3. **文献名称**:*Functional analysis of acute intermittent porphyria mutations in the HMBS gene*
**作者**:M. Yasuda et al.
**摘要**:利用重组HMBS突变体研究卟啉症相关基因突变的酶活性缺陷,建立了体外疾病模型用于药物筛选。
---
**领域覆盖**:
- **表达系统**(原核表达优化)
- **结构生物学**(催化机制解析)
- **疾病机制**(突变体功能研究)
如需扩展,可补充哺乳动物细胞表达体系或酶动力学研究相关文献。
HMBS (hydroxymethylbilane synthase), also known as porphobilinogen deaminase (PBGD), is a critical enzyme in the heme biosynthesis pathway. It catalyzes the polymerization of four porphobilinogen (PBG) molecules into hydroxymethylbilane, a linear tetrapyrrole precursor for heme and chlorophyll. Genetic mutations in the HMBS gene can lead to acute intermittent porphyria (AIP), an autosomal dominant metabolic disorder characterized by the accumulation of neurotoxic porphyrin precursors. This enzyme is therefore of significant interest in both clinical diagnostics and therapeutic research.
Recombinant HMBS protein is typically produced using heterologous expression systems such as E. coli, yeast, or mammalian cells. The E. coli system offers cost-effective production but may lack post-translational modifications, while mammalian expression systems (e.g., CHO or HEK293 cells) better mimic human protein structures. Recombinant HMBS retains catalytic activity and serves as a vital tool for studying enzyme kinetics, substrate interactions, and inhibitor screening. Its applications extend to developing enzyme replacement therapies for AIP patients and creating diagnostic assays to measure porphyrin precursor levels.
Recent advances in protein engineering have focused on improving HMBS stability and catalytic efficiency. Modified versions with enhanced thermostability or reduced immunogenicity are being explored for therapeutic use. Structural studies using recombinant HMBS have revealed key residues involved in substrate binding and catalytic mechanisms, informing drug design for porphyria management. Challenges remain in optimizing production yields and ensuring proper folding in recombinant systems, particularly for maintaining long-term activity in therapeutic applications. Ongoing research also investigates HMBS's potential role in photodynamic therapy and its interactions with other heme biosynthesis enzymes.
×